Last 48 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Zimmer Biomet Holdings, Inc.'s quarterly P/E stands at 18.5x, down 40.4% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 11.0% YoY to 11.6x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 23.48 | 18.53 | 32.11 | 21.23 | 29.61 | 31.09 | 22.01 | 21.94 | 22.99 | 39.28 | 15.14 | 36.44 | 36.40 |
| — | -40.4% | +45.9% | -3.2% | +28.8% | -20.8% | +45.4% | -39.8% | -36.8% | +35.0% | — | +28.2% | +1.2% | |
| P/S Ratio | 1.98 | 2.12 | 1.98 | 2.45 | 2.18 | 2.96 | 2.61 | 3.00 | 2.88 | 3.60 | 3.27 | 3.36 | 4.09 |
| — | -28.3% | -23.9% | -18.6% | -24.5% | -17.8% | -20.2% | -10.6% | -29.4% | -3.0% | -10.7% | +2.1% | +31.8% | |
| P/B Ratio | 1.30 | 1.20 | 1.40 | 1.53 | 1.44 | 1.82 | 1.69 | 1.77 | 1.76 | 2.16 | 2.03 | 1.88 | 2.47 |
| — | -34.1% | -17.2% | -13.3% | -17.9% | -15.6% | -16.8% | -6.0% | -28.8% | -3.4% | -8.5% | +4.9% | +35.5% | |
| P/FCF | 11.09 | 13.71 | 6.66 | 8.97 | 15.17 | 16.83 | 12.53 | 14.86 | 25.11 | 52.50 | 12.08 | 26.63 | 38.53 |
| — | -18.5% | -46.8% | -39.7% | -39.6% | -67.9% | +3.7% | -44.2% | -34.8% | +90.8% | -67.4% | +95.6% | +117.4% | |
| EV / EBITDA | 9.47 | 11.56 | 10.82 | 10.40 | 10.98 | 12.98 | 10.26 | 13.10 | 11.70 | 16.16 | 12.91 | 14.16 | 15.85 |
| — | -11.0% | +5.4% | -20.6% | -6.2% | -19.7% | -20.5% | -7.5% | -26.2% | +10.7% | -67.8% | -0.6% | +17.4% | |
| EV / EBIT | 17.07 | 16.45 | 36.40 | 18.61 | 20.65 | 24.05 | 19.09 | 24.42 | 19.68 | 30.68 | 22.95 | 26.60 | 27.37 |
| — | -31.6% | +90.7% | -23.8% | +4.9% | -21.6% | -16.8% | -8.2% | -28.1% | +25.9% | — | -13.9% | -5.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Zimmer Biomet Holdings, Inc.'s operating margin was 17.9% in Q1 2026, up 5.1 pp QoQ and up 2.6 pp YoY. The trailing four-quarter average of 15.7% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.6% | 72.4% | 64.7% | 72.1% | 71.5% | 71.2% | 71.0% | 70.5% | 71.5% | 72.9% | 72.2% | 70.4% | 71.9% |
| — | +1.7% | -8.9% | +2.2% | -0.0% | -2.3% | -1.7% | +0.1% | -0.6% | +0.3% | +1.0% | -0.5% | +0.8% | |
| Operating Margin | 16.5% | 17.9% | 12.8% | 17.6% | 14.4% | 15.3% | 19.2% | 15.3% | 18.1% | 14.1% | 18.3% | 15.2% | 17.6% |
| — | +16.8% | -33.3% | +14.6% | -20.2% | +8.8% | +5.3% | +0.8% | +2.6% | -21.3% | +1277.4% | +3.5% | +11.8% | |
| Net Margin | 8.6% | 11.4% | 6.2% | 11.5% | 7.4% | 9.5% | 11.8% | 13.7% | 12.5% | 9.1% | 21.6% | 9.3% | 11.2% |
| — | +19.7% | -47.5% | -15.5% | -41.2% | +4.5% | -45.2% | +47.2% | +11.5% | -28.1% | +402.2% | -20.1% | +30.0% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.6% | 1.7% | 1.1% | 1.8% | 1.2% | 1.5% | 1.9% | 2.0% | 1.9% | 1.4% | 3.4% | 1.3% | 1.7% |
| — | +18.6% | -43.2% | -7.9% | -36.1% | +6.4% | -42.5% | +51.7% | +12.2% | -28.5% | +412.0% | -17.9% | +34.2% | |
| ROA | 3.2% | 1.0% | 0.6% | 1.0% | 0.7% | 0.8% | 1.1% | 1.2% | 1.1% | 0.8% | 2.0% | 0.8% | 1.0% |
| — | +24.4% | -46.1% | -13.5% | -40.0% | +4.1% | -43.4% | +50.5% | +14.7% | -27.0% | +418.8% | -15.6% | +38.1% | |
| ROIC | 5.4% | 1.4% | 1.1% | 1.3% | 1.2% | 1.2% | 1.6% | 1.2% | 1.5% | 1.1% | 1.5% | 1.1% | 1.4% |
| — | +12.1% | -31.3% | +17.0% | -18.2% | +8.4% | +7.2% | +2.1% | +4.3% | -20.7% | +1324.3% | +7.8% | +18.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Zimmer Biomet Holdings, Inc.'s Debt/EBITDA ratio is 14.0x, up from 13.1x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 20.7% YoY to 2.94x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.59 | 0.51 | 0.59 | 0.64 | 0.60 | 0.58 | 0.50 | 0.52 | 0.46 | 0.46 | 0.46 | 0.44 | 0.46 |
| — | -12.4% | +19.0% | +22.0% | +31.9% | +25.7% | +7.6% | +18.9% | -0.7% | -3.4% | -2.4% | -6.1% | -7.2% | |
| Debt / EBITDA | 3.06 | 13.96 | 13.15 | 12.78 | 13.24 | 13.13 | 9.51 | 12.16 | 9.81 | 11.49 | 9.69 | 10.80 | 10.07 |
| — | +6.3% | +38.3% | +5.1% | +34.9% | +14.3% | -1.9% | +12.6% | -2.5% | +10.9% | -66.0% | -9.9% | -14.2% | |
| Current Ratio | 1.98 | 2.94 | 1.98 | 2.43 | 1.87 | 2.44 | 1.91 | 1.36 | 1.29 | 1.66 | 1.61 | 2.11 | 1.96 |
| — | +20.7% | +4.0% | +78.3% | +45.6% | +47.1% | +18.2% | -35.5% | -34.5% | -12.3% | -14.1% | +6.9% | +8.4% | |
| Quick Ratio | 1.10 | 1.61 | 1.10 | 1.39 | 0.96 | 1.46 | 0.99 | 0.70 | 0.63 | 0.80 | 0.78 | 0.99 | 0.95 |
| — | +10.3% | +10.3% | +99.6% | +53.1% | +81.8% | +27.7% | -29.4% | -33.5% | -13.7% | -19.5% | -5.6% | -0.5% | |
| Interest Coverage | 3.84 | 5.47 | 2.36 | 4.70 | 3.83 | 4.46 | 5.67 | 5.24 | 6.91 | 5.24 | 6.66 | 5.29 | 6.36 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying ZBH stock.
Zimmer Biomet Holdings, Inc.'s current P/E is 23.5x. The average P/E over the last 4 quarters is 25.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Zimmer Biomet Holdings, Inc.'s current operating margin is 16.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Zimmer Biomet Holdings, Inc.'s business trajectory between earnings reports.